The epidemiologic burden of hepatitis C virus infection in Latin America
Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurate estimates of disease prevalence to assess the potential impact of new treatment...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2012-09-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119314358 |
| _version_ | 1818602795780014080 |
|---|---|
| author | Shelagh M. Szabo Meagan Bibby Yong Yuan Bonnie M.K. Donato R. Jiménez-Mendez G. Castañeda-Hernández Maribel Rodríguez-Torres Adrian R. Levy |
| author_facet | Shelagh M. Szabo Meagan Bibby Yong Yuan Bonnie M.K. Donato R. Jiménez-Mendez G. Castañeda-Hernández Maribel Rodríguez-Torres Adrian R. Levy |
| author_sort | Shelagh M. Szabo |
| collection | DOAJ |
| description | Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurate estimates of disease prevalence to assess the potential impact of new treatments. However, few estimates of the epidemiologic burden, either overall or by country, are available for Latin America; and the potential impact of currently-available treatments on the epidemiologic burden of HCV in Latin America has not been assessed. To address this, we systematically reviewed twenty-five articles presenting population-based estimates of HCV prevalence from general population or blood donor samples, and supplemented those with publically-available data, to estimate the total number of persons infected with HCV in Latin America at 7.8 million (2010). Of these, over 4.6 million would be expected to have genotype 1 chronic HCV, based on published data on the risk of progression to chronic disease and the HCV genotype distribution of Latin America. Finally, we calculated that between 1.6 and 2.3 million persons with genotype 1 chronic HCV would potentially benefit from current treatments, based on published estimates of genotypespecific treatment responsiveness. In conclusion, these estimates demonstrate the substantial present epidemiologic burden of HCV, and quantify the impending societal and clinical burden from untreated HCV in Latin America. |
| first_indexed | 2024-12-16T13:12:58Z |
| format | Article |
| id | doaj.art-1c20dca579e84f98b575a4d9a6da1d0b |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-16T13:12:58Z |
| publishDate | 2012-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-1c20dca579e84f98b575a4d9a6da1d0b2022-12-21T22:30:33ZengElsevierAnnals of Hepatology1665-26812012-09-01115623635The epidemiologic burden of hepatitis C virus infection in Latin AmericaShelagh M. Szabo0Meagan Bibby1Yong Yuan2Bonnie M.K. Donato3R. Jiménez-Mendez4G. Castañeda-Hernández5Maribel Rodríguez-Torres6Adrian R. Levy7Oxford Outcomes Ltd., CanadaOxford Outcomes Ltd., CanadaBristol-Myers Squibb, United StatesBristol-Myers Squibb, United StatesUniversity of British Columbia, CanadaCINVESTAV-IPN, MexicoFundación de Investigación de Diego, United StatesOxford Outcomes Ltd., Canada; Dalhousie University, Canada; Correspondence and reprint request:Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurate estimates of disease prevalence to assess the potential impact of new treatments. However, few estimates of the epidemiologic burden, either overall or by country, are available for Latin America; and the potential impact of currently-available treatments on the epidemiologic burden of HCV in Latin America has not been assessed. To address this, we systematically reviewed twenty-five articles presenting population-based estimates of HCV prevalence from general population or blood donor samples, and supplemented those with publically-available data, to estimate the total number of persons infected with HCV in Latin America at 7.8 million (2010). Of these, over 4.6 million would be expected to have genotype 1 chronic HCV, based on published data on the risk of progression to chronic disease and the HCV genotype distribution of Latin America. Finally, we calculated that between 1.6 and 2.3 million persons with genotype 1 chronic HCV would potentially benefit from current treatments, based on published estimates of genotypespecific treatment responsiveness. In conclusion, these estimates demonstrate the substantial present epidemiologic burden of HCV, and quantify the impending societal and clinical burden from untreated HCV in Latin America.http://www.sciencedirect.com/science/article/pii/S1665268119314358HCVPrevalenceLiver diseaseBurdenSystematic review |
| spellingShingle | Shelagh M. Szabo Meagan Bibby Yong Yuan Bonnie M.K. Donato R. Jiménez-Mendez G. Castañeda-Hernández Maribel Rodríguez-Torres Adrian R. Levy The epidemiologic burden of hepatitis C virus infection in Latin America Annals of Hepatology HCV Prevalence Liver disease Burden Systematic review |
| title | The epidemiologic burden of hepatitis C virus infection in Latin America |
| title_full | The epidemiologic burden of hepatitis C virus infection in Latin America |
| title_fullStr | The epidemiologic burden of hepatitis C virus infection in Latin America |
| title_full_unstemmed | The epidemiologic burden of hepatitis C virus infection in Latin America |
| title_short | The epidemiologic burden of hepatitis C virus infection in Latin America |
| title_sort | epidemiologic burden of hepatitis c virus infection in latin america |
| topic | HCV Prevalence Liver disease Burden Systematic review |
| url | http://www.sciencedirect.com/science/article/pii/S1665268119314358 |
| work_keys_str_mv | AT shelaghmszabo theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT meaganbibby theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT yongyuan theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT bonniemkdonato theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT rjimenezmendez theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT gcastanedahernandez theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT maribelrodrigueztorres theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT adrianrlevy theepidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT shelaghmszabo epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT meaganbibby epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT yongyuan epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT bonniemkdonato epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT rjimenezmendez epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT gcastanedahernandez epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT maribelrodrigueztorres epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica AT adrianrlevy epidemiologicburdenofhepatitiscvirusinfectioninlatinamerica |